Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-KNIH-31-07-2017-05:26:38:019-1197 - samples

ABSTRACT: A IPS02_N_NPC_WGBS paired end data for Neural progenitor cells(Nestin)

PROVIDER: EGAD00001003474 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

ena-DATASET-KNIH-31-07-2017-05:29:57:796-1200 - samples

Project description:A IPS05_X_NPC_WGBS paired end data for Neural progenitor cells(Nestin)

| EGAD00001003477 | EGA

ena-DATASET-KNIH-31-07-2017-05:52:51:642-1228 - samples

Project description:A IPS05_X_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin)

| EGAD00001003505 | EGA

ena-DATASET-KNIH-31-07-2017-05:44:08:813-1215 - samples

Project description:A IPS05_X_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin)

| EGAD00001003492 | EGA

ena-DATASET-KNIH-31-07-2017-05:50:59:011-1225 - samples

Project description:A IPS02_N_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin)

| EGAD00001003502 | EGA

ena-DATASET-KNIH-31-07-2017-05:42:22:798-1212 - samples

Project description:A IPS02_N_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin)

| EGAD00001003489 | EGA

Sequentially acting Sox transcription factors in neural lineage development [microarray]

Project description:We report sequential binding but unique functions of different Sox transcription factors during distinct stages of neural differentiation We used microarray to examine the molecular function of Sox3 in neural progenitor cells. Over-expression of Sox3 under Nestin-promoter in neural progenitor cells. Cells are transgenic for GFP in Sox1 locus and were FACS sorted to obtain pure populations.

2011-11-01 | E-GEOD-33061 | biostudies-arrayexpress

SRSF10 regulates proliferation of neural progenitor cells and affects neurogenesis in the developing mouse neocortex

Project description:To identify the potential functions of SRSF10 in neural progenitor cells and neocortex development, we constructed SRSF10 flox/flox mice, and conditionally knock out the SRSF10 in the neural progenitor cells by breeding with Nestin-Cre mice.

2023-05-30 | GSE225647 | GEO

Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans.

Project description:Bullous pemphigoid (BP) is the most common autoimmune skin blistering disease characterized by autoimmunity against the hemidesmosomal proteins BP180, type XVII collagen, and BP230. To elucidate the genetic basis of susceptibility to BP, we performed the first genome-wide association study (GWAS) in Germans. This GWAS was combined with HLA locus targeted sequencing in an additional independent BP cohort. The strongest association with BP in Germans tested in this study was observed in the two HLA loci, HLA-DQA1*05:05 and HLA-DRB1*07:01. Further studies with increased sample sizes and complex studies integrating multiple pathogenic drivers will be conducted.

| S-EPMC8136166 | biostudies-literature

Gene Expression Analysis of Nestin-creERT2, or NG2-creERTM driven P53f/f; Nf1f/+; Ptenf/+ mouse GBM

Project description:We have developed spontaneous genetically engineered GBM mouse models from two distinct cells of origin: subventricular zone neural stem cells (SVZ; Nestin-creERT2) and oligodendrocyte lineage progenitor cells (OPC; NG2-creERTM). These tumors are biologically separable and are reflective of their lineage of origin.

2020-03-31 | GSE127273 | GEO

CTNI-07. DELIVERY AND ACTIVITY OF SN-38 BY SACITUZUMAB GOVITECAN IN CNS TUMORS

Project description:Abstract BACKGROUND Sacituzumab Govitecan (SG, TRODELVY™) is an antibody drug conjugate, with payload and linker characteristics preferable for CNS delivery. SG utilizes a pH hydrolysable linker, allowing SN-38 to be released at the tumor site. SN-38 is the active component of Irinotecan and 1000-fold more potent than the parent compound. We observed SG activity in intracranial xenografts and hypothesized that SG would achieve therapeutically relevant concentration of SN-38 within the CNS. METHODS We performed a prospective, single center, window of opportunity trial (NCT03995706) to examine the intra-tumoral concentrations of SG, SN-38, and SN-38G in patients undergoing craniotomy for breast cancer brain metastases (BCBM, n=10) or recurrent glioblastoma (rGBM, n=10). Patients received a single dose of SG at 10mg/kg IV the day prior to craniotomy and tumor collected. [SN-38] was analyzed via mass spectrometry (UHPLC-HRMS). Patients resumed SG 10mg/kg IV days 1 and 8 of 21 day cycle following recovery and were assessed every third cycle by MRI using RANO criteria. RESULTS To date 16 patients have been treated, including 8 BCBM and 8 rGBM. UHPLC-HRMS analysis was performed in the first 10 tumors (n=4 and 6 respectively). For the rGBM patients, total concentration of SN-38 varied from 93nM to 680nM, with a mean concentration of 420nM. For BCBM, total concentration of SN-38 varied from 173nM to 1160nM, with a mean concentration of 626nM. All GBM patients had residual measurable disease and 4 breast patients had measurable disease. With a median follow-up of 12 weeks from the first postoperative cycle in the first 14 patients, 2 partial responses from each group were observed (ORR of 28% and 50% at 12 weeks respectively). CONCLUSIONS SG achieves therapeutically relevant concentrations of SN-38 at 40-fold mean IC50s for GBM, and 150-fold mean IC50s for BCBM. Early intracranial responses are encouraging and merit further evaluation.

| S-EPMC7650388 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data